90 related articles for article (PubMed ID: 23129735)
1. Mast cell sarcoma: a rare and aggressive entity--report of two cases and review of the literature.
Georgin-Lavialle S; Aguilar C; Guieze R; Lhermitte L; Bruneau J; Fraitag S; Canioni D; Chandesris MO; Suarez F; Grandpeix-Guyodo C; Damaj G; Barete S; Aouba A; Fite C; Robert C; Gaulard P; Lortholary O; Tournilhac O; Dubreuil P; Hermine O
J Clin Oncol; 2013 Feb; 31(6):e90-7. PubMed ID: 23129735
[No Abstract] [Full Text] [Related]
2. Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis?
Falleti J; Borgia L; Lalinga AV; De Cecio R; Natella V; Patitucci G; Vita G
Pathol Res Pract; 2012 Nov; 208(11):683-6. PubMed ID: 22963840
[TBL] [Abstract][Full Text] [Related]
3. Pediatric mast cell sarcoma of temporal bone with novel L799F (2395 C>T) KIT mutation, mimicking histiocytic neoplasm.
Kim YS; Wu H; Pawlowska AB; Bautista-Quach MA; Huang Q; Gaal K; Chang KL
Am J Surg Pathol; 2013 Mar; 37(3):453-8. PubMed ID: 23388130
[TBL] [Abstract][Full Text] [Related]
4. Mastocytosis: state of the art.
Horny HP; Sotlar K; Valent P
Pathobiology; 2007; 74(2):121-32. PubMed ID: 17587883
[TBL] [Abstract][Full Text] [Related]
5. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
[TBL] [Abstract][Full Text] [Related]
6. Mast cell sarcoma: clinical management.
Weiler CR; Butterfield J
Immunol Allergy Clin North Am; 2014 May; 34(2):423-32. PubMed ID: 24745684
[TBL] [Abstract][Full Text] [Related]
7. Mast cell sarcoma in an infant: a case report and review of the literature.
Bautista-Quach MA; Booth CL; Kheradpour A; Zuppan CW; Rowsell EH; Weiss L; Wang J
J Pediatr Hematol Oncol; 2013 May; 35(4):315-20. PubMed ID: 23211696
[TBL] [Abstract][Full Text] [Related]
8. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
9. A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone.
Baghestanian M; Bankl Hc; Sillaber C; Beil WJ; Radaszkiewicz T; Füreder W; Preiser J; Vesely M; Schernthaner G; Lechner K; Valent P
Leukemia; 1996 Jan; 10(1):159-66. PubMed ID: 8558922
[TBL] [Abstract][Full Text] [Related]
10. Mast cell tryptase and microphthalmia transcription factor effectively discriminate cutaneous mast cell disease from myeloid leukemia cutis.
Sundram UN; Natkunam Y
J Cutan Pathol; 2007 Apr; 34(4):289-95. PubMed ID: 17381798
[TBL] [Abstract][Full Text] [Related]
11. Tandem duplication of KIT exon 11 influences the proteome of canine mast cell tumours.
Schlieben P; Meyer A; Weise C; Bondzio A; Gruber AD; Klopfleisch R
J Comp Pathol; 2013 May; 148(4):318-22. PubMed ID: 22935087
[TBL] [Abstract][Full Text] [Related]
12. Morphologic and immunophenotypic properties of neoplastic cells in a case of mast cell sarcoma.
Chott A; Guenther P; Huebner A; Selzer E; Parwaresch RM; Horny HP; Valent P
Am J Surg Pathol; 2003 Jul; 27(7):1013-9. PubMed ID: 12826896
[TBL] [Abstract][Full Text] [Related]
13. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
14. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
15. Internalization of Kit together with stem cell factor on human fetal liver-derived mast cells: new protein and RNA synthesis are required for reappearance of Kit.
Shimizu Y; Ashman LK; Du Z; Schwartz LB
J Immunol; 1996 May; 156(9):3443-9. PubMed ID: 8617971
[TBL] [Abstract][Full Text] [Related]
16. Reduced immunostaining for c-kit receptors in mucosal mast cells in inflammatory bowel disease.
Farhadi A; Keshavarzian A; Fields JZ; Jakate S; Shaikh M; Banan A
J Gastroenterol Hepatol; 2007 Dec; 22(12):2338-43. PubMed ID: 17645464
[TBL] [Abstract][Full Text] [Related]
17. Clinical, biological, and molecular characteristics of clonal mast cell disorders presenting with systemic mast cell activation symptoms.
Alvarez-Twose I; González de Olano D; Sánchez-Muñoz L; Matito A; Esteban-López MI; Vega A; Mateo MB; Alonso Díaz de Durana MD; de la Hoz B; Del Pozo Gil MD; Caballero T; Rosado A; Sánchez Matas I; Teodósio C; Jara-Acevedo M; Mollejo M; García-Montero A; Orfao A; Escribano L
J Allergy Clin Immunol; 2010 Jun; 125(6):1269-1278.e2. PubMed ID: 20434205
[TBL] [Abstract][Full Text] [Related]
18. Current state of biology and diagnosis of clonal mast cell diseases in adults.
Alvarez-Twose I; Morgado JM; Sánchez-Muñoz L; García-Montero A; Mollejo M; Orfao A; Escribano L
Int J Lab Hematol; 2012 Oct; 34(5):445-60. PubMed ID: 22551157
[TBL] [Abstract][Full Text] [Related]
19. Solitary mastocytoma with histologic features of eosinophilic cellulites.
Zeng YP; Ma DL
Eur J Dermatol; 2011; 21(4):602-3. PubMed ID: 21540136
[No Abstract] [Full Text] [Related]
20. C-Kit controls IL-1β-induced effector functions in HMC-cells.
Drube S; Schmitz F; Göpfert C; Weber F; Kamradt T
Eur J Pharmacol; 2012 Jan; 675(1-3):57-62. PubMed ID: 22173128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
